Alcon Inc. logo

Alcon Inc. (ALC)

Market Closed
10 Jul, 20:00
NYSE NYSE
$
88. 70
+1.72
+1.98%
$
43.42B Market Cap
- P/E Ratio
1.06% Div Yield
1,624,229 Volume
- Eps
$ 86.98
Previous Close
Day Range
87.58 89.46
Year Range
80.48 101.1
Want to track ALC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 40 days
Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter

Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter

GENEVA--(BUSINESS WIRE)--Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter.

Businesswire | 3 months ago
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space

3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space

ALC, GKOS and REGN are well-positioned to benefit from the evolving space of cell-based ophthalmic therapy.

Zacks | 3 months ago
Alcon (ALC) Soars 6.0%: Is Further Upside Left in the Stock?

Alcon (ALC) Soars 6.0%: Is Further Upside Left in the Stock?

Alcon (ALC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks | 3 months ago
Alcon Stock Might Rise as Clareon Vivity IOL Secures CE Mark Approval

Alcon Stock Might Rise as Clareon Vivity IOL Secures CE Mark Approval

ALC secures CE Mark for Clareon Vivity IOL, bringing advanced presbyopia-correcting lens technology to Europe, enhancing visual outcomes with cutting-edge innovation.

Zacks | 3 months ago
ALC Stock Rises Following the Merger Agreement With LENSAR

ALC Stock Rises Following the Merger Agreement With LENSAR

Alcon enters into a definitive merger agreement to acquire LENSAR's ALLY Robotic Cataract Laser Treatment System, proprietary Streamline software technology and LENSAR legacy laser system.

Zacks | 3 months ago
Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities

Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities

GENEVA--(BUSINESS WIRE)--Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities.

Businesswire | 3 months ago
Alcon Agrees to Acquire LENSAR, Inc.

Alcon Agrees to Acquire LENSAR, Inc.

GENEVA, Switzerland & ORLANDO, Fla.--(BUSINESS WIRE)--Alcon Agrees to Acquire LENSAR, Inc.

Businesswire | 3 months ago
Retinal Surgery Devices Market Outlook Report 2025-2033: Revenues Set to Double, Reaching $4.83 Billion by 2033, Led by Topcon Corp., Alcon, and Carl Zeiss

Retinal Surgery Devices Market Outlook Report 2025-2033: Revenues Set to Double, Reaching $4.83 Billion by 2033, Led by Topcon Corp., Alcon, and Carl Zeiss

Dublin, March 24, 2025 (GLOBE NEWSWIRE) -- The "Retinal Surgery Devices Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" has been added to ResearchAndMarkets.com's offering. The Retinal Surgery Devices Market is expected to reach US$ 4.84 billion in 2033 from US$ 2.48 billion in 2024, with a CAGR of 7.71% from 2025 to 2033. Some of the main reasons propelling the market include the rising prevalence of a number of eye ailments, increased awareness of eye issues and available treatments, and the expanding use of minimally invasive (MI) surgical technology. Rising prevalence of retinal diseases The market for retinal surgery instruments is mostly driven by the increasing incidence of retinal disorders. Age-related macular degeneration (AMD), diabetic retinopathy, and retinal detachment are among the conditions that are growing increasingly prevalent, especially as the world's population ages and the prevalence of diabetes rises. The need for sophisticated retinal surgery equipment, including lasers, vitrectomy tools, and surgical microscopes, is increasing since these conditions frequently call for surgical intervention. The demand for specialist surgical instruments is boosted by more surgeries performed as a result of early diagnosis and greater awareness of these disorders. Market growth and innovation in the industry are still being propelled by this trend. Around 2.2 billion people worldwide suffer from near or distant vision impairment, of which nearly 1 billion cases may have been avoided, according to a WHO report published in October 2021. It demonstrates the high prevalence of visual impairment patients globally as well as the potential for therapy. Because of this, the demand for ophthalmic medications is quite high, which will favorably affect the market's growth over the study's projected period. Increasing Geriatric Population One major factor propelling the market for retinal surgery instruments is the aging population. People are more vulnerable to age-related retinal disorders include diabetic retinopathy, macular degeneration, and retinal detachment as they get older. By 2050, there will be about 2 billion people worldwide who are 60 years of age or older, up from 900 million in 2015, according to figures from the World Health Organization (WHO) in 2021. Approximately 125 million people are 80 years of age or older at the moment.

Globenewswire | 3 months ago
Is it the Right Time to Hold Alcon Stock in Your Portfolio Now?

Is it the Right Time to Hold Alcon Stock in Your Portfolio Now?

ALC stays on investors' radar due to its Surgical arm performance and contributions from new products.

Zacks | 3 months ago
Alcon to Host 2025 Capital Markets Day

Alcon to Host 2025 Capital Markets Day

GENEVA--(BUSINESS WIRE)--Alcon to Host 2025 Capital Markets Day.

Businesswire | 3 months ago
Alcon to Host 2025 Capital Markets Day

Alcon to Host 2025 Capital Markets Day

GENEVA--(BUSINESS WIRE)--Alcon to Host 2025 Capital Markets Day.

Businesswire | 3 months ago
Algoma Central Corporation Takes Delivery of Three Vessels Within One Week

Algoma Central Corporation Takes Delivery of Three Vessels Within One Week

ST. CATHARINES, Ontario--(BUSINESS WIRE)-- #yourmarinecarrierofchoice--Algoma Central Corporation (“Algoma”, “Company”) (TSX: ALC) has achieved a significant milestone, taking delivery of three new ships, from three different countries, within one week for the first time in Company history. Since 2013, Algoma has built 23 vessels with 12 more on order or under construction. “This milestone reflects Algoma's commitment to making significant capital investments to meet our customers' needs - in the U.S., Canada, and internat.

Businesswire | 4 months ago
Loading...
Load More